Published in Rare Tumors on December 09, 2014
Mutations of KRAS, NRAS, BRAF, EGFR, and PIK3CA genes in urachal carcinoma: Occurence and prognostic significance. Oncotarget (2016) 0.75
National Incidence, Management and Survival of Urachal Carcinoma. Rare Tumors (2016) 0.75
Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med (2007) 39.39
Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med (2011) 11.93
Urachal carcinoma: clinicopathologic features and long-term outcomes of an aggressive malignancy. Cancer (2006) 3.08
Malignant urachal lesions. J Urol (1984) 2.99
Multimodality management of urachal carcinoma: the M. D. Anderson Cancer Center experience. J Urol (2003) 2.41
Urachal carcinoma: a clinicopathologic analysis of 24 cases with outcome correlation. Am J Surg Pathol (2009) 2.32
Risk of bleeding with vascular endothelial growth factor receptor tyrosine-kinase inhibitors sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials. Lancet Oncol (2009) 2.23
The clinical epidemiology of urachal carcinoma: results of a large, population based study. J Urol (2012) 1.88
The Urachus: its Anatomy, Histology and Development. J Anat (1930) 1.42
Understanding the molecular-based mechanism of action of the tyrosine kinase inhibitor: sunitinib. Anticancer Drugs (2010) 1.34
Urachal adenocarcinoma: a clinician's guide for treatment. Semin Oncol (2012) 1.16
Oxaliplatin, irinotecan and capecitabine as first-line therapy in metastatic colorectal cancer (mCRC): a dose-finding study and pharmacogenomic analysis. Br J Cancer (2010) 0.96
Urachal adenocarcinoma metastatic to the ovaries resembling primary ovarian mucinous carcinoma: a case report with the immunohistochemical study. Int J Clin Exp Pathol (2010) 0.93
Adenocarcinoma of the urachus associated with elevated levels of CA 125. J Urol (1991) 0.89
Management of mucinous urachal neoplasm presenting as pseudomyxoma peritonei. Tumori (2008) 0.88
Feasibility study of biweekly capecitabine, oxaliplatin, and irinotecan in patients with untreated advanced gastric cancer. Tumori (2009) 0.82
Urachal carcinoma associated with increased carbohydrate antigen 19-9 and carcinoembryonic antigen. J Urol (2001) 0.82